melatonin has been researched along with Tension-Type Headache in 5 studies
Tension-Type Headache: A common primary headache disorder, characterized by a dull, non-pulsatile, diffuse, band-like (or vice-like) PAIN of mild to moderate intensity in the HEAD; SCALP; or NECK. The subtypes are classified by frequency and severity of symptoms. There is no clear cause even though it has been associated with MUSCLE CONTRACTION and stress. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the differences in cortisol and melatonin concentrations between children with frequent episodic tension-type headache (FETTH) and healthy children." | 7.77 | Salivary cortisol and melatonin levels in children with frequent episodic tension-type headache do not differ from healthy children. ( Ambite-Quesada, S; Arroyo-Morales, M; Fernández-de-las-Peñas, C; Fernández-Mayoralas, DM; Linares-García-Valdecasas, R; Palomar-Gallego, MA; Rivas-Martínez, I, 2011) |
| "To investigate the differences in cortisol and melatonin concentrations between children with frequent episodic tension-type headache (FETTH) and healthy children." | 3.77 | Salivary cortisol and melatonin levels in children with frequent episodic tension-type headache do not differ from healthy children. ( Ambite-Quesada, S; Arroyo-Morales, M; Fernández-de-las-Peñas, C; Fernández-Mayoralas, DM; Linares-García-Valdecasas, R; Palomar-Gallego, MA; Rivas-Martínez, I, 2011) |
| "Migraine is one of the most severe and debilitating primary headache disorders." | 2.61 | Therapeutic role of melatonin in migraine prophylaxis: A systematic review. ( Long, R; Zhou, S; Zhu, Y, 2019) |
| "Models of sleep physiology and insomnia are discussed, along with the potential implications for the chronification of migraine and tension-type headache." | 2.48 | Chronic headaches and insomnia: working toward a biobehavioral model. ( Ong, JC; Park, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liampas, I | 1 |
| Siokas, V | 1 |
| Brotis, A | 1 |
| Mentis, AA | 1 |
| Aloizou, AM | 1 |
| Dastamani, M | 1 |
| Tsouris, Z | 1 |
| Lima, M | 1 |
| Dardiotis, E | 1 |
| Long, R | 1 |
| Zhu, Y | 1 |
| Zhou, S | 1 |
| Miano, S | 1 |
| Parisi, P | 1 |
| Pelliccia, A | 1 |
| Luchetti, A | 1 |
| Paolino, MC | 1 |
| Villa, MP | 1 |
| Rivas-Martínez, I | 1 |
| Ambite-Quesada, S | 1 |
| Fernández-de-las-Peñas, C | 1 |
| Arroyo-Morales, M | 1 |
| Fernández-Mayoralas, DM | 1 |
| Linares-García-Valdecasas, R | 1 |
| Palomar-Gallego, MA | 1 |
| Ong, JC | 1 |
| Park, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Melatonin for Adolescent Migraine Prevention Study (The MAP Study).[NCT03150797] | Phase 2 | 72 participants (Actual) | Interventional | 2017-08-02 | Terminated (stopped due to Insufficient Fund) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in mean migraine/migrainous days from weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase for each group. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | -1 |
| Placebo Oral Capsule | 0 |
Mean CASQ score in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. The CASQ is a 16-question instrument that uses Likert-like responses and has a score range from 16-80; higher scores indicate greater sleepiness (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | points (Mean) |
|---|---|
| Melatonin 3mg | 33 |
| Melatonin 6mg | 36 |
| Placebo Oral Capsule | 28 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 3 mg vs. placebo. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. melatonin 3 mg. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. placebo. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo. (Ultimately, as the data were not normally distributed, medians were more appropriate). (NCT03150797)
Timeframe: weeks 5-8 of randomized treatment phase
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Number of days acute medication is used in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to the number of days that medication for the acute treatment of headache was used during the time frame. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 5 |
| Melatonin 6mg | 3 |
| Placebo Oral Capsule | 3 |
Number of headache days in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to number of headache days during the time period--regardless of whether they were migraine or not. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 8 |
| Melatonin 6mg | 4 |
| Placebo Oral Capsule | 5 |
3 reviews available for melatonin and Tension-Type Headache
| Article | Year |
|---|---|
Endogenous melatonin levels and therapeutic use of exogenous melatonin in tension type headache: A systematic review.
Topics: Adult; Analgesics; Case-Control Studies; Child; Humans; Melatonin; Tension-Type Headache | 2021 |
Therapeutic role of melatonin in migraine prophylaxis: A systematic review.
Topics: Central Nervous System Depressants; Humans; Melatonin; Migraine Disorders; Observational Studies as | 2019 |
Chronic headaches and insomnia: working toward a biobehavioral model.
Topics: Actigraphy; Adaptation, Psychological; Caffeine; Chronobiology Phenomena; Comorbidity; Headache Diso | 2012 |
1 trial available for melatonin and Tension-Type Headache
| Article | Year |
|---|---|
Melatonin to prevent migraine or tension-type headache in children.
Topics: Adolescent; Age Factors; Central Nervous System Depressants; Child; Consciousness Disorders; Female; | 2008 |
1 other study available for melatonin and Tension-Type Headache
| Article | Year |
|---|---|
Salivary cortisol and melatonin levels in children with frequent episodic tension-type headache do not differ from healthy children.
Topics: Case-Control Studies; Child; Depression; Female; Humans; Hydrocortisone; Male; Melatonin; Saliva; Te | 2011 |